Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
letter
. 2022 Apr 15;65(8):1677–1679. doi: 10.1007/s11427-022-2110-1

A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a Randomized, Double-Blinded Clinical Trial

Yu Cao 1,#, Xiaoli Wang 2,#, Siqi Li 2,#, Yuan Dong 1, Yonghong Liu 2, Jing Li 3, Yanqing Zhao 3, Yingmei Feng 1,✉
PMCID: PMC9020148  PMID: 35441932

The content is available as a PDF (380.1 KB).

Acknowledgements

We thanked Dr. Mingling Tao and Dr. Sha Meng for the technical assistance during participant recruitment and randomization. This work was supported by grants from the Beijing Science Foundation of China (Z201100005520062 and Z201100007920017).

Supporting Information

Materials and methods (426.7KB, pdf)

Compliance and ethics The author(s) declare that they have no conflict of interest. The study protocol was approved by Beijing Youan Hospital Ethics Committee (No. 2021-77). The trial complies with the Helsinki Declaration for research in human subjects.

Footnotes

Contributed equally to this work

References

  1. Cao Y, Yisimayi A, Bai Y, Huang W, Li X, Zhang Z, Yuan T, An R, Wang J, Xiao T, et al. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell Res. 2021;31:732–741. doi: 10.1038/s41422-021-00514-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, San JE, Cromer D, Scheepers C, Amoako DG, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602:654–656. doi: 10.1038/s41586-021-04387-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Lauring, A. S., Tenforde, M. W., Chappell, J. D., Gaglani, M., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Talbot, H. K., Casey, J. D., et al. (2022). Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational Study. medRxiv doi:10.1101/2022.02.06.22270558. [DOI] [PMC free article] [PubMed]
  4. Peiris, M., Cheng, S., Mok, C.K.P., Leung, Y., Ng, S., Chan, K., Ko, F., Yiu, K., Lam, B., Lau, E., et al. (2022). Neutralizing antibody titres to SARS-CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with mRNA BNT162b2 or inactivated CoronaVac vaccines. Nature Portfolio doi:10.21203/rs.3.rs1207071/v1.
  5. Newman, J., Thakur, N., Peacock, T. P., Bialy, D., Elreafey, A. M., Bogaardt, C., Horton, D. L., Ho, S., Kankeyan, T., Carr, C., et al. (2021). Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2. medRxiv doi:10.1101/2021.12.23.21268293. [DOI] [PMC free article] [PubMed]
  6. Pérez-Then, E., Lucas, C., Monteiro, V. S., Miric, M., Brache, V., Cochon, L., Vogels, C. B. F., De la Cruz, E., Jorge, A., De los Santos, M., et al. (2021). Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: the Dominican Republic Experience. medRxiv doi:10.1101/2021.12.27.21268459.
  7. Pulliam, J. R. C., van Schalkwyk, C., Govender, N., von Gottberg, A., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021). Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv doi:10.1101/2021.11.11.21266068. [DOI] [PMC free article] [PubMed]
  8. Wang K, Jia Z, Bao L, Wang L, Cao L, Chi H, Hu Y, Li Q, Zhou Y, Jiang Y, et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature. 2022;603:919–925. doi: 10.1038/s41586-022-04466-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Wang X, Zhao X, Song J, Wu J, Zhu Y, Li M, Cui Y, Chen Y, Yang L, Liu J, et al. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerging Microbes Infects. 2022;11:477–481. doi: 10.1080/22221751.2022.2030200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, Wu Z, Jiang D, Deng X, Chu K, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022;22:483–495. doi: 10.1016/S1473-3099(21)00681-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Science China. Life Sciences are provided here courtesy of Nature Publishing Group

RESOURCES